Ad blocking detected

Thank you for visiting We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Lexagene Holdings Inc. (V:LXG)

Business Focus: Bio Diagnostics & Testing

Sector:  Healthcare Industry:  Biotechnology & Medical Research
See Regulatory Filings on SEDAR
Company Contact
Address: 500 Cummings Ctr Ste 4550
BEVERLY MA 01915-6534
Tel: N/A
IR: See website
Key People
John F. Regan
Chairman of the Board, Chief Executive Officer
Jeffrey Mitchell
Chief Financial Officer, Treasurer, Corporate Secretary
Steven Armstrong
Director - Operations
Eleanor Kolossovski
Director of Product Marketing
Business Overview
Lexagene Holdings Inc. is a molecular diagnostics company. The Company is focused on developing a fully automated, rapid pathogen detection system for use at the point-of-need where samples are collected, which offers unprecedented ease-of-use, sensitivity, and breadth of pathogen detection. The Company's MiQLab is an automated, open-access molecular diagnostic system for pathogen detection, allowing users to test for multiple pathogens onsite, returning results in approximately 2 hours. Its on-site, automated rapid pathogen detection technology is used for testing in human clinical diagnostics, veterinary diagnostics, food safety, and more. Its veterinary diagnostics system enables veterinarians to rapidly identify infectious pathogens and antibiotic resistance factors in cats and dogs, providing actionable insights in initial diagnosis and prescribed therapies.
Financial Overview
For the six months ended 31 August 2021, LexageneHoldings Inc revenues increased from $0K to $41K. Net lossincreased 21% to $5.5M. Revenues reflect an increase indemand for the Company's products and services due tofavorable market conditions. Higher net loss reflectsSalaries increase of 38% to $1.8M (expense), Salariesincrease from $309K to $776K (expense).
Employees: 34 as of Feb 28, 2021
Reporting Currency: U.S. Dollars
Enterprise value: $50.02M as of Aug 31, 2021
Annual revenue (TTM): $0.13M as of Aug 31, 2021
EBITDA (TTM): -$13.14M as of Aug 31, 2021
Net annual income (TTM): -$13.89M as of Aug 31, 2021
Free cash flow (TTM): -$14.02M as of Aug 31, 2021
Net Debt Last Fiscal Year: N/A
Shares outstanding: 119,267,322 as of Nov 1, 2021
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization